Serial Number:
90779972
Mark:
FYCACI
Status:
Third Extension-Granted
Status Date:
04-05-2024
Filing Date:
Registration Number:
N/A
Registration Date:
N/A
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use in the nature of monoclonal antibodies for medical purposes
Mark Description:
N/A
Class:
Pharmaceutical and veterinary preparations
Type of Mark:
Trademark
Published for Opposition Date:
09-27-2022
Owner:
Mark Drawing Status:
Standart Character Mark
Abandon Date:
N/A
Business Name:
BRISTOL-MYERS SQUIBB COMPANY
Correspondent Name:
